Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: April 3, 2010 (53-week fiscal year)
Business Overview: Haemonetics is a global healthcare company providing blood management solutions, including automated blood component collection devices, surgical blood salvage systems, and information technology platforms. The company operates as a single segment with four product families: Plasma, Blood Bank, Hospital, and Software Solutions. Approximately 87% of revenues are derived from single-use proprietary consumables.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 | Change |
|---|---|---|---|
| Net Revenues | $645.4 million | $597.9 million | +8.0% |
| Gross Profit | $337.5 million | $308.2 million | +9.5% |
| Gross Margin | 52.3% | 51.5% | +80 bps |
| Operating Income | $83.3 million | $85.6 million | -2.7% |
| Net Income | $58.4 million | $59.3 million | -1.6% |
| Diluted EPS | $2.24 | $2.27 | -1.3% |
| Cash & Equivalents | $141.6 million | $156.7 million | -9.6% |
| Total Debt | $20.7 million | $6.0 million | +243% |
| Working Capital | $249.6 million | $289.5 million | -13.8% |
Material Changes vs. Prior Period
- Revenue Growth: Driven by an 8.1% increase in disposable sales (plasma and platelet volume growth) and acquisitions (Neoteric, SEBRA, Global Med). Foreign exchange contributed a 1.9% favorable impact.
- Operating Income Decline: Despite revenue growth, operating income fell 2.7% due to significant one-time charges:
- Asset Impairments: $15.7 million write-down of intangible assets (abandonment of Portico platelet apheresis software and Symphony blood bank software).
- Restructuring Costs: $8.6 million primarily for employee separation benefits related to the Global Med acquisition integration.
- Acquisition Costs: $2.2 million in transaction costs for the Global Med acquisition.
- Debt Increase: Total debt rose to $20.7 million, primarily due to $7.8 million in notes payable assumed in the Global Med acquisition and $7.5 million in short-term notes payable by the Japanese subsidiary.
- Product Mix: Plasma disposables revenue grew 14.9%, while Red Cell disposables revenue declined 3.0% due to reduced market demand.
Guidance, Outlook, and Risks
- Strategic Outlook: Management continues to focus on the "blood management solutions" vision, integrating devices with software and consulting services. The company expects to launch the IMPACT Online platform for blood collectors in fiscal 2011.
- Future Costs: The company expects to incur an additional $6.4 million in cash restructuring costs and $1.5 million in integration costs in fiscal 2011.
- Share Repurchases: The Board authorized a new $50.0 million share repurchase program for fiscal 2011.
- Key Risks:
- Customer Concentration: The Japan Red Cross Society accounted for 14.3% of total revenues.
- Legal Proceedings: An ongoing patent infringement lawsuit against Fenwal Inc. resulted in an $18.0 million award (damages and royalties), which is currently under appeal and escrowed.
- Foreign Exchange: Approximately 53% of revenues are generated outside the U.S., exposing the company to currency fluctuations (primarily Euro and Yen).
- Regulatory: Subject to FDA and international regulations; potential for new excise taxes on medical devices.
Investor Verification Checklist
- Asset Impairment Rationale: Verify the strategic decision to abandon the Portico and Symphony software projects and the impact on future R&D pipelines.
- Global Med Integration: Monitor the realization of synergies and the execution of the $6.4 million in expected future restructuring costs.
- Japan Red Cross Dependency: Assess the stability of the relationship with the Japan Red Cross, which represents a significant portion of revenue and accounts receivable.
- Patent Litigation Status: Track the appeal of the Fenwal patent infringement case to determine the likelihood of collecting the $18.0 million award.
- Red Cell Market Trends: Evaluate the sustainability of the decline in red cell disposable revenue and the company's strategy to counteract donor shortages.